A5013311116- Lymphoma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lung Cancer Treatments and Mutations
- Hepatocellular Carcinoma Treatment and Prognosis
- CNS Lymphoma Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Viral-associated cancers and disorders
- Cancer Genomics and Diagnostics
- Chronic Lymphocytic Leukemia Research
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Cancer, Lipids, and Metabolism
- Cancer Treatment and Pharmacology
- Vascular Tumors and Angiosarcomas
- Peptidase Inhibition and Analysis
- Sarcoma Diagnosis and Treatment
- Helicobacter pylori-related gastroenterology studies
- DNA Repair Mechanisms
- Cutaneous lymphoproliferative disorders research
- Liver Disease Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Metastasis and carcinoma case studies
Samsung Medical Center
2013-2025
Sungkyunkwan University
2013-2025
University of Nevada, Las Vegas
2022-2025
Samsung (South Korea)
2023-2025
ABL Bio (South Korea)
2023
Merck Serono (Switzerland)
2023
AstraZeneca (Brazil)
2023
Palmetto Hematology Oncology
2023
Korea University
2023
Soongsil University
2023
Adjuvant chemotherapy and chemoradiotherapy are some of the standards care for gastric cancer (GC). The chemoRadioTherapy In Stomach Tumors (ARTIST) 2 trial compares two adjuvant regimens in patients with D2-resected, stage II or III, node-positive GC.The ARTIST compared, a 1:1:1 ratio, three regimens: oral S-1 (40-60 mg twice daily 4 weeks on/2 off) 1 year, (2 on/1 week plus oxaliplatin 130 mg/m2 every 3 (SOX) 6 months, SOX 45 Gy (SOXRT). Randomization was stratified according to surgery...
Abstract The VIKTORY (targeted agent eValuation In gastric cancer basket KORea) trial was designed to classify patients with metastatic based on clinical sequencing and focused eight different biomarker groups (RAS aberration, TP53 mutation, PIK3CA mutation/amplification, MET amplification, overexpression, all negative, TSC2 deficient, or RICTOR amplification) assign one of the 10 associated trials in second-line (2L) treatment. Capivasertib (AKT inhibitor), savolitinib (MET selumetinib (MEK...
Abstract Sequence alterations in microsatellites and an elevated mutational burden are observed 20% of gastric cancers associated with clinical response to anti–PD-1 antibodies. However, 50% microsatellite instability–high (MSI-H) intrinsically resistant PD-1 therapies. We conducted a phase II trial pembrolizumab patients advanced MSI-H cancer included serial multi-region tissue samples addition peripheral blood analyses. The number whole-exome sequencing (WES)–derived nonsynonymous...
Abstract Background A limited number of studies have characterized genomic properties hepatocellular carcinoma (HCC) patients in response to anti-PD-1 immunotherapy. Methods Herein, we performed comprehensive molecular characterization immediate (D-42 D-1) pre-treatment tumor biopsy specimens from 60 with sorafenib-failed HCC a single-arm prospective phase II trial pembrolizumab. Objective rate was the primary efficacy endpoint. We used whole-exome sequencing, RNA and correlative analysis....
Abstract Regorafenib has anti-tumor activity in patients with unresectable hepatocellular carcinoma (uHCC) potential immunomodulatory effects, suggesting that its combination immune checkpoint inhibitor may have clinically meaningful benefits uHCC. The multicenter, single-arm, phase 2 RENOBATE trial tested regorafenib–nivolumab as front-line treatment for Forty-two received nivolumab 480 mg every 4 weeks and regorafenib 80 daily (3-weeks-on/1-week-off schedule). primary endpoint was the...
Abstract Purpose: Ceralasertib is a potent and selective oral inhibitor of the serine/threonine protein kinase ataxia telangiectasia Rad3-related (ATR) protein. Patients Methods: Eligible patients with solid tumors, enriched for melanoma, received ceralasertib in combination fixed dose paclitaxel (80 mg/m2 on D1, D8, D15) 28-day cycles. The was escalated to reach an MTD rolling 6 design. starting 40 mg QD. Fifty-seven (33 melanoma who failed prior PD1/L1 treatment) were enrolled 7 cohorts...
Abstract Background & Aims Atezolizumab plus bevacizumab (Ate/Bev) has demonstrated efficacy and safety in patients with advanced hepatocellular carcinoma (HCC) the phase III trial. Further evaluation is necessary to investigate of Ate/Bev real settings. Methods This was a multicentre retrospective analysis. Between May 2020 February 2021, 138 received as first‐line treatment for HCC from 11 institutions. We excluded Child‐Pugh B or C BCLC D stage, remaining 121 were included this...
Background Targeting the DNA damage repair (DDR) pathways is an attractive strategy for boosting cancer immunotherapy. Ceralasertib (AZD6738) oral kinase inhibitor of ataxia telangiectasia and Rad3 related protein, which a master regulator DDR. We conducted phase II trial ceralasertib plus durvalumab in patients with previously treated advanced gastric (AGC) to demonstrate safety, tolerability, clinical activity combination. Methods This II, open-label, single-center, non-randomized study...
Although the incidence of young-onset digestive tract cancers is increasing worldwide, their risk factors remain largely unknown. We investigated association between nonalcoholic fatty liver disease (NAFLD) and cancers.This nationwide cohort study included 5,265,590 individuals age 20-39 years who underwent national health screening under Korean National Health Insurance Service 2009 2012. The index was used as a diagnostic biomarker for NAFLD. participants were followed up until December...
Alterations in claudin expression can impair tight junction function, influence signaling pathways, and act as a tumor-promoting event some epithelial cancers. Recently, zolbetuximab, highly potent tumor cell-selective therapeutic antibody against 18.2, has been developed investigated clinical trials.We conducted prospective study using 18.2 immunohistochemistry 430 consecutive patients with advanced gastrointestinal, genitourinary, or rare cancers between June 2012 March 2016.Claudin was...
Regorafenib is an approved agent in patients with advanced hepatocellular carcinoma (HCC) who progressed on sorafenib, but little known about its clinical outcomes Child-Pugh B patients. We aimed to investigate the safety and effectiveness of regorafenib HCC patients.This multicentre retrospective study included 59 received regorafenib. Comparative analyses were performed independent cohort class A from same registry (n = 440).The median age was 58 years (range, 19-83). All had progression...
An accurate and comprehensive assessment of lymph node metastasis in patients with head neck squamous cell cancer is crucial daily practice. This study constructed a predictive model risk scoring system based on CT characteristics nodes tumors for carcinoma to stratify the metastasis.Data included 476 cervical from 191 historical cohort. We analyzed preoperative images nodes, including diameter, ratio long-to-short axis necrosis, conglomeration, infiltration adjacent soft tissue, laterality...
Regorafenib demonstrated a clinical benefit for patients with unresectable hepatocellular carcinoma (uHCC) in the phase III RESORCE trial. Considering heterogeneity of uHCC and discrepancies its characteristics between prospective trials daily practice, real-life evidence is necessary.This multicentre, retrospective analysis was performed by Korean Cancer Study Group. In total, 440 who received regorafenib January 2017 November 2019 were identified nine tertiary referral hospitals Korea.All...
Abstract The association between non-alcoholic fatty liver disease (NAFLD) and the risk of pancreatic cancer in general population remains unclear. This nationwide cohort study included 8,120,674 adults who underwent a national health screening 2009 from Korean National Health Insurance Service database. Participants were followed-up until December 2017 for development cancer. NAFLD was assessed using index: ≥ 60, < 30, no NAFLD. Multivariable Cox proportional hazards regression...
Background and AimsNivolumab is the first immune checkpoint inhibitor for hepatocellular carcinoma (HCC). External beam radiation therapy (EBRT) locally effective may enhance effectiveness of immunotherapy. This study investigated efficacy safety concurrent nivolumab EBRT in HCC with macrovascular invasion.MethodsIn this phase 2 multicenter trial, patients invasion were concurrently treated intravenous (3 mg/kg every weeks) EBRT, followed by maintenance until progression or unacceptable...